Home > Drugs A – Z > Riociguat (By mouth)

Riociguat (By mouth)

Treats pulmonary hypertension.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Riociguat is used to treat adults with chronic thromboembolic pulmonary hypertension (CTEPH) that can be treated after surgery, or that cannot be treated with surgery. Riociguat is also used to treat adults with pulmonary arterial hypertension (PAH), by relaxing these blood vessels and increasing the supply of blood to the lungs, which reduces the workload of the heart. This medicine is available… Read more
Brand names include
Adempas
Drug classes About this
Cardiovascular Agent

What works? Research summarized

Evidence reviews

Riociguat (Adempas): Management of Inoperable Chronic Thromboembolic Pulmonary Hypertension [Internet]

Chronic thromboembolic pulmonary hypertension (CTEPH) is a disease subtype of pulmonary hypertension. It is a progressive disease characterized by the presence of non-resolving or recurrent thrombi distributed within the pulmonary arteries. This can obstruct or occlude the luminal space, eventually leading to increased pulmonary vascular resistance (PVR), pulmonary hypertension, and right-sided heart failure. Although the exact etiology of CTEPH remains poorly understood, it may arise following an initial episode of acute pulmonary embolism (PE); however, up to 60% of CTEPH patients have not had any antecedent episode of acute PE. The epidemiology of CTEPH is likewise not well established. Some surveillance data estimate CTEPH to occur in 0.1% to 0.5% of patients surviving an initial episode of acute PE; however, the true incidence of CTEPH is likely to be higher, owing to an unknown number of undetected cases either presenting occultly or latently in the setting of acute PE or through non-venous thromboembolism etiologies.

Drugs for Pulmonary Arterial Hypertension: Comparative Efficacy, Safety, and Cost-Effectiveness [Internet]

The objective of this therapeutic review is to conduct a systematic review to assess the comparative efficacy and safety and to determine the cost-effectiveness of drug therapies for the treatment of pulmonary arterial hypertension (PAH) in adults.

Soluble guanylate cyclase stimulators for raised blood pressure within the lungs

We reviewed the use of a set of drugs, soluble guanylate cyclase stimulators, for the improvement of symptoms in participants with pulmonary hypertension (PH). This was in comparison to current treatment or no treatment.

See all (8)

Summaries for consumers

Soluble guanylate cyclase stimulators for raised blood pressure within the lungs

We reviewed the use of a set of drugs, soluble guanylate cyclase stimulators, for the improvement of symptoms in participants with pulmonary hypertension (PH). This was in comparison to current treatment or no treatment.

PubMed Health Blog...

read all...